Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus Chemotherapy in Adjuvant NSCLC
NCT05825443Phase 2Recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Apr 2023
- Primary completion
- Apr 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in non-small cell lung cancer (NSCLC), sponsored by Nanfang Hospital, Southern Medical University. Started Apr 2023; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05825443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05825443.